Theralase Technologies Inc (TSXV:TLT)
C$ 0.26 0.015 (6.12%) Market Cap: 64.42 Mil Enterprise Value: 64.41 Mil PE Ratio: 0 PB Ratio: 29.48 GF Score: 50/100

Q2 2024 Theralase Technologies Inc Earnings Call Transcript

Aug 21, 2024 / 03:00PM GMT
Release Date Price: C$0.195 (+5.41%)
Matthew Perraton
Theralase Technologies Inc - Independent Chairman of the Board

Good morning, everyone. My name is Matthew Perraton, and I will be hosting the Theralase Technologies Inc., quarterly investor conference call today. Today's call will focus on a presentation and discussion of the Company's second quarter 2024 interim financial statements and our Phase two bladder cancer clinical study results, followed by a question and answer period for each.

The agenda for the call today will be first a presentation by Kristina Hachey, Chief Financial Officer of Theralase on the second quarter interim financial statements, followed by a question-and-answer period regarding the results. Second, once the review of the financial statements has been completed. RRoger Dumoulin-White, President and Chief Executive Officer of Theralase, will provide us an update on the Phase two bladder cancer clinical study also followed by a question-and-answer period regarding the results.

Before we begin, I would like to remind everyone that today's presentation may contain forward-looking statements

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot